December 9, 2011
Press Release Briefingwire.com
Immune Response BioPharma, Inc. Licenses U.S. Patent 8,053,197 Key TCR Patent from OHSU Provides Strong IP Protection for NeuroVax MS Vaccination.
Immune Response BioPharma, Inc. Licenses U.S. Patent 8,053,197 a Key TCR Patent from OHSU which provides the Company a Strong IP Protection for NeuroVax MS Vaccination and the other indications with TCR Peptide Vaccination technology including RA, Psoriasis and Crohn’s Disease.
“Partnering with OHSU is a great achievement for our company and we thank OHSU, licensing this new key patent gives us a strong IP position for NeuroVax and the pipeline. U.S. Patent 8,053,197 extends IP coverage into 2027 and gives IRBP the FOXP3 Expression technology which inhibits autoimmune disease and provides us with a strong platform to launch NeuroVax for MS as we prepare for a new Phase 2B clinical trial” Mr. Buswell COO IRBP.
“Our friends at OHSU have worked very hard on this technology over the years including Dr. Vandenbark, Dr. Bartholomew and Dr. Offner all contributed to this invention and key patent thus credit goes to them for their hardwork. IRBP is proud to partner with OHSU and we are building a world class biopharmaceutical company with world class technology like the FOXP3 Expression technology which inhibits autoimmune diseases. This is the first of many licensing and partnering opportunities yet to come as we build the next great biopharmaceutical company” Mr. Buswell COO IRBP.
Forward-Looking Statement
Some of the statements made in this press release are forward looking in nature. These statements are based on management’s current expectations or beliefs. These forward looking statements are not a guarantee of performance and are subject to a number of uncertainties and other factors, many of which are outside Immune Response BioPharma, Inc.’s control, which could cause actual events to differ materially from those expressed or implied by the statements. The most important factors that could prevent Immune Response BioPharma, Inc. from achieving its stated goals include, but are not limited to: the current uncertainty in the global financial markets and the global economy. Including but not limited to the uncertainties regarding the approval of biopharmaceutical products in a highly regulated market.
Immune Response BioPharma is a diversified biopharmaceutical company engaged in the process of developing lifesaving drugs and therapeutic vaccines in the auto-immune, infectious disease areas. IRBP’s proprietary pipeline includes first in class treatments REMUNE for AIDS, NeuroVax for MS and Sepsicillin for Sepsis Shock. The company has a deep pipeline of experimental drugs it plans to develop.
Plans to raise capital is neither an offer nor solicitation for sale of securities. Forward looking statements are based upon future projections, timeframes and current information and IRBP makes no guarantee that its products will be successful or approved in a highly regulated market. Clinical trials and data may not be sufficient to satisfy regulatory requirements. Safe Harbor disclosure.
Immune Response BioPharma may be found on the world wide web at www.immuneresponsebiopharma.com
